论文部分内容阅读
原位心脏移植(HTX)公认是小儿和成人终末期心脏病的治疗方法。近10年来HTX已成功地应用于新生儿和婴儿。该年龄组HTX数占儿童期HTX总数近一半。少数有经验的移植中心,通过改进术中处理使该年龄组HTX5年生存率高于大龄小儿和成人移植组。等待供体心脏时间过长仍然是患儿术前死亡原因。供体短缺、术前处理、改善外科替代治疗是影响婴儿移植的主要因素。
Orthotopic heart transplantation (HTX) is recognized as a treatment for end-stage heart disease in children and adults. HTX has been successfully applied to newborns and infants in the past 10 years. HTX in this age group accounts for nearly half of all childhood HTX. A small number of experienced transplant centers have improved the annual survival rate of HTX5 in this age group by increasing intraoperative management. Waiting for the donor heart is still a long time before the cause of death in children with preoperative. Donor shortage, preoperative treatment, and surgical surgeries are the main factors influencing infant transplants.